Comparison
Cagrilintide vs. Matrixyl
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Cosmetic
CAS no.
1415456-99-3
214047-00-4
Molecular weight
4253.7 g/mol
802.06 g/mol
Half-life
168 h
no data
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYPalmitoyl-Lys-Thr-Thr-Lys-SerMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1